<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HF44C66C2241B42E4818C411FCCEB0DAE" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 3269 IH: Eliminating Thickets to Increase Competition Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-05-08</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 3269</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250508">May 8, 2025</action-date><action-desc><sponsor name-id="A000375">Mr. Arrington</sponsor> (for himself, <cosponsor name-id="D000399">Mr. Doggett</cosponsor>, <cosponsor name-id="I000056">Mr. Issa</cosponsor>, <cosponsor name-id="J000298">Ms. Jayapal</cosponsor>, and <cosponsor name-id="P000048">Mr. Pfluger</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HJU00">Committee on the Judiciary</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To address patent thickets.</official-title></form><legis-body id="H0B0DE140BD9940FDBFC483B3FB3DA028" style="OLC"> 
<section id="H24433B14CD8F42229AD61401B8C1E14E" section-type="section-one"><enum>1.</enum><header>Short title</header>
 <text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Eliminating Thickets to Increase Competition Act</short-title></quote> or the <quote><short-title>ETHIC Act</short-title></quote>.</text></section>
<section id="HCE7EE2651A8741FAA741734FE5D685CC"><enum>2.</enum><header>Addressing patent thickets</header> 
<subsection id="H56BF1130629E4D83B7C0CEFDEDBC0CB8"><enum>(a)</enum><header>Limit on number of patents per patent group that may be asserted in action for infringement</header><text>Section 271(e) of title 35, United States Code, is amended by adding at the end the following:</text> <quoted-block style="OLC" display-inline="no-display-inline" id="HE2E375EFF98143CC90A6F8C9237F85B5"> <paragraph id="HEE8B3E0E9B4E4CA18CDF89F4DB0ED3BC" indent="up1"><enum>(7)</enum> <subparagraph commented="no" display-inline="yes-display-inline" id="HE536935239C244C0845CFB733D5AFA14"><enum>(A)</enum><text>A person who brings an action for infringement of a patent under this section against a party described in subparagraph (B) may assert in the action not more than one patent per Patent Group.</text></subparagraph> 
<subparagraph id="HC9ED138816F6467D8DED5E6DE3F9B985" indent="up1"><enum>(B)</enum><text>A party described in this subparagraph is—</text> <clause commented="no" display-inline="no-display-inline" id="H11394A6866CF481FA349128D35B6FC81"><enum>(i)</enum><text>a person who—</text> 
<subclause commented="no" display-inline="no-display-inline" id="H8DB4B719D65D4EDDB7E710243CDF919E"><enum>(I)</enum><text>submits an application for approval of a drug under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>), or is a holder of such an approved application; or</text></subclause> <subclause commented="no" display-inline="no-display-inline" id="H9233348480E64E7BACAA01A1D3D1C671"><enum>(II)</enum><text>submits an application for licensure of a biological product under section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>), or is a holder of such a licensure; or</text></subclause></clause> 
<clause commented="no" display-inline="no-display-inline" id="HB81740119E5F45D0A7E2B791D1CB3189"><enum>(ii)</enum><text>a person making, using, selling, offering for sale, introducing or delivering into interstate commerce, or importing—</text> <subclause commented="no" display-inline="no-display-inline" id="H0BE5A8495C2F4778A8F8EA20C855D39A"><enum>(I)</enum><text display-inline="yes-display-inline">a drug approved pursuant to an application under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>); or</text></subclause> 
<subclause commented="no" display-inline="no-display-inline" id="H81519847342D4BEC8DA03D52CA6ACEAA"><enum>(II)</enum><text>a biological product licensed under section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>).</text></subclause></clause></subparagraph> <subparagraph commented="no" display-inline="no-display-inline" indent="up1" id="HDB619D39CE064740B5B716EB98661CDB"><enum>(C)</enum><text>A person who brings an action described in subparagraph (A) asserting a patent against a party may not bring any additional actions described in that subparagraph asserting a patent in the same Patent Group against that party.</text></subparagraph> 
<subparagraph commented="no" display-inline="no-display-inline" indent="up1" id="H177AF370B100475390E78723B5D91F57"><enum>(D)</enum> 
<clause commented="no" display-inline="yes-display-inline" id="H102E7F48894447DD931BB8E9A42DCF13"><enum>(i)</enum><text>For purposes of this paragraph, the term <term>Patent Group</term> means 2 or more commonly owned patents or applications that—</text> <subclause commented="no" display-inline="no-display-inline" indent="up1" id="H79FEE4E69DAF40FEBFC08A8BDA4F2BD0"><enum>(I)</enum><text>are identified on 1 or more disclaimers under section 253 to another commonly owned patent; or</text></subclause> 
<subclause commented="no" display-inline="no-display-inline" indent="up1" id="H8F5EDD22AE45416EAC0C97AA74FE4E80"><enum>(II)</enum><text>are subject to 1 or more disclaimers under section 253 to another commonly owned patent.</text></subclause></clause> <clause commented="no" display-inline="no-display-inline" indent="up1" id="HBB16C88F7354433C90E2E3ABBDEC1334"><enum>(ii)</enum><text>For purposes of clause (i)(I)—</text> 
<subclause commented="no" display-inline="no-display-inline" id="HCE7AA0D2EF84483D9F12D7F74D28055E"><enum>(I)</enum><text display-inline="yes-display-inline">each patent or application that identifies the same patent or application on a disclaimer under section 253 is part of the same Patent Group; and</text></subclause> <subclause commented="no" display-inline="no-display-inline" id="HB5D6A9F40AC04D70BBB424CD6C1272A0"><enum>(II)</enum><text>each patent or application that is identified on a disclaimer under section 253 is part of the same Patent Group as the patent or application subject to the disclaimer.</text></subclause></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection> 
<subsection id="HBE18924B3F264E498B3B77CFBC5A14F6"><enum>(b)</enum><header>Applicability</header><text>The amendment made by subsection (a) shall apply with respect to an application submitted under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>) on or after the date of enactment of this Act.</text></subsection></section> </legis-body></bill>

